Peripheral Matters | Can Evolocumab Benefit PAD Patients?

Major adverse cardiovascular and limb events are reduced with evolocumab added to statin therapy in patients with symptomatic lower extremity peripheral arterial disease (PAD) – even in those without a history of myocardial infarction (MI) or stroke. These are among the findings of a new analysis from the FOURIER study presented at AHA 2017 and published in Circulation. Marc P. Bonaca, MD, MPH, et al., write that “the relationship between achieved LDL-C and lower risk of limb events extended down to very low achieved levels of LDL-C.” And these “benefits come with no offsetting safety concerns.”